The Complicated Urinary Tract Infection (cUTI) market is expected to witness substantial growth through 2034, supported by rising disease prevalence, increasing antimicrobial resistance (AMR), and a robust late-stage antibiotic pipeline, according to DelveInsight’s Complicated Urinary Tract Infection Market Insights, Epidemiology, and Forecast – 2034. The report provides a detailed analysis of market size, treatment landscape, epidemiology trends, drug uptake, and competitive dynamics across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Complicated Urinary Tract Infection Market Size and Forecast
In 2025, the cUTI market size across the 7MM was valued at approximately USD 1.37 billion and is projected to grow at a compound annual growth rate (CAGR) of 5.7%, reaching nearly USD 2.26 billion by 2034. Growth is primarily fueled by hospital-acquired infections, increased catheter-associated urinary tract infections (CAUTIs), and expanding use of advanced beta-lactam/beta-lactamase inhibitor combinations.
Get a Free sample for the Complicated Urinary Tract Infection Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market
Late-Stage Pipeline and Complicated Urinary Tract Infection Emerging Therapies
The cUTI treatment pipeline is evolving rapidly, with several Phase III and late-stage antibiotics targeting multidrug-resistant (MDR) and carbapenem-resistant pathogens. In March 2025, Meiji Seika Pharma reported positive Phase III results for Nacubactam (OP0595), a novel β-lactamase inhibitor addressing antimicrobial resistance in cUTI and acute pyelonephritis. Earlier, in January 2025, Wockhardt announced that ZAYNICH achieved a 96.8% clinical cure rate in a pivotal global Phase III trial, meeting superiority endpoints required for regulatory approval.
Complicated Urinary Tract Infection Epidemiology Trends and Patient Pool Analysis
In 2024, the United States reported approximately 3.56 million diagnosed incident cUTI cases, with women accounting for nearly 70% of cases. The disease burden is highest among elderly populations aged 65 years and above, emphasizing the growing impact of aging demographics on cUTI epidemiology. Across the 7MM, more than 10.7 million treated cUTI cases were reported, including first-line and recurrent infections.
To Know in detail about the Complicated Urinary Tract Infection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Complicated Urinary Tract Infection Market Forecast
Complicated Urinary Tract Infection Competitive Landscape and Key Players
The competitive landscape includes leading pharmaceutical and biotechnology companies such as Allecra Therapeutics, Merck Sharp & Dohme, AbbVie, Shionogi, Melinta Therapeutics, Spero Therapeutics, Wockhardt, Meiji, Venatorx Pharmaceuticals, and Evopoint Pharmaceuticals. Key marketed and emerging therapies include EXBLIFEP, RECARBRIO, AVYCAZ/ZAVICEFTA, FETROJA, VABOMERE, Tebipenem Pivoxil Hydrobromide, Cefepime-zidebactam, Cefepime/taniborbactam, OP0595, and XNW4107.
Complicated Urinary Tract Infection Market Drivers and Barriers
Major market drivers include the rising use of urinary catheters, increasing antibiotic demand, growing awareness of antimicrobial resistance, and supportive regulatory pathways for novel anti-infectives. Key market barriers include the limited availability of potent oral antibiotics, high development costs, and stringent regulatory requirements for antibacterial drug approval.
Complicated Urinary Tract Infection Market Outlook Through 2034
With multiple late-stage pipeline assets, expanding hospital-based treatment demand, and continued investment in next-generation antibiotics, the complicated urinary tract infection market is poised for sustained growth through 2034.
To know more about Complicated Urinary Tract Infection companies working in the treatment market, visit @ Complicated Urinary Tract Infection Clinical Trials and Therapeutic Assessment
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
